{
  "docId": "019de074-ead2-732b-8415-93449fe93e32",
  "docSlug": "9cc66a7a8f583a45c6978147aa12db97",
  "documentTitle": "Freeman Capital Management | Activist Presentation Deck | 95 slides",
  "authorId": "freeman-capital-management",
  "authorName": "Freeman Capital Management",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 95,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "problem_statement",
  "function": "diagnose_problem",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "Uses a three-column layout to categorize grievances.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ead2-732b-8415-93449fe93e32/13",
  "deckHref": "/decks/019de074-ead2-732b-8415-93449fe93e32",
  "deckJsonHref": "/decks/019de074-ead2-732b-8415-93449fe93e32.json",
  "deckAnchorHref": "/decks/019de074-ead2-732b-8415-93449fe93e32#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "Poor Corporate Governance and Management Entrenchment",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3cffc9c5-2c6d-4293-9fd8-bd3cec043e47",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.65,
        "y": 0.25
      },
      "kind": "list",
      "text": "Inexperienced and Unqualified Management",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c353a86-4ec2-4843-a0fb-8ec27ed62533",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.35,
        "y": 0.25
      },
      "kind": "list",
      "text": "Disconnected Pay for Performance",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dbcf5ac3-0466-4839-ae8f-9ba02c2da6a2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.05,
        "y": 0.4
      },
      "kind": "paragraph",
      "text": "Board approved off-market golden parachutes for all of management, following FCM's calls for accountability.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76a7d713-f82d-462d-a6d2-4c9489ebe085",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.25,
        "x": 0.35,
        "y": 0.4
      },
      "kind": "paragraph",
      "text": "In 2021 and 2022, MindMed spent over $51 million on director and executive compensation. MindMed is the only company in its peer group to offer directors RSUs or DDSU rather than just cash and options. Board provided full bonuses to management for normal course expectations, regulatory compliance and even when MindMed failed to meet its goals. Board gave themselves a “one-time” 3-fold raise in 2022.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d6477dc-c454-416e-b240-89eba1fca98d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.65,
        "y": 0.4
      },
      "kind": "paragraph",
      "text": "CEO Robert Barrow has NEVER brought a drug to market nor run a pivotal trial. He has just three years of psychedelic experience. CMO Danial Karlin’s experience is in bioinformatics and digital medicine, not drug development.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "be2bd772-b9b0-4510-985b-6da2f210f266",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Company SEC Filings. See [5]",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "358b9f1d-0e9d-4d7d-b4ff-6202d2a2fd61",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.5,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "The Irrefutable Need For Change",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "02f50b37-ea41-4f0a-be99-087740befe59",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 7,
      "beatId": "85b7cc19-6bf1-4224-9106-c9aec7c4aad5",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem (Identify pain)",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "The document identifies the company's severe market underperformance and flawed approach to clinical development as key problems.",
      "position": 0,
      "confidence": 0.9,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "736778a8-67e9-479d-853c-8d29821dfcab",
      "evidence": "The document highlights the company's severe market underperformance and the need for change.",
      "position": 0,
      "objective": "What is the cost of inaction for Mind Medicine's shareholders?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.8,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}